Company Name, Ticker, Competitors, else..

Regenxbio Inc (NASDAQ: RGNX)

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Regenxbio Inc 's

Name: Regenxbio Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RGNX Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Regenxbio Inc reported Revenue increase in the 2 quarter 2026 by 405.73 % year on year.
The sales growth was above Regenxbio Inc 's competitors' average revenue growth of 47.21 %, achieved in the same quarter.

• List of RGNX Competitors

With a net margin of 21.02 % Regenxbio Inc achieved higher profitability than its competitors.

• More on RGNX Profitability Comparisons

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Regenxbio Inc achieved net profit of $22.71 millions compared to a net loss of $-70.87 millions recorded in the same quarter a year ago.

<< RGNX Stock Performance Comparisons

<< See the full list of RGNX competitors

Overall company Market Share Q2 2026

Due to outstanding performance in Overall company, revenue grew by 405.73 % Regenxbio Inc improved its market share, to approximately 5.85 %. << More on RGNX Market Share.

*Market share is calculated based on total revenue.

RGNX's Stock Performance relative to its Competitors

Publicly Traded Peers of Regenxbio Inc

Champions Oncology Inc
Share Performance

-13.99%

This Quarter

Champions Oncology Inc

Profile

Champions Oncology Inc's business model involves offering personalized medicine solutions by conducting experiments on tumor samples acquired directly from patients and then delivering data-driven reports to help physicians make informed decisions about patient treatment options. They also provide drug development services to pharmaceutical companies, enabling them to test the efficacy of new cancer treatments in a preclinical setting.

More about Champions Oncology Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 68.376 mill.	$ 60.662 mill.	$ 0.039 mill.

Immunocore Holdings Plc
Share Performance

-9.45%

Over The Past 5 Days

Immunocore Holdings Plc

Profile

The company develops bispecific T cell receptor therapeutics targeting cancer, infectious diseases, and autoimmune disorders.

More about Immunocore Holdings Plc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,667.609 mill.	$ 430.775 mill.	$ -18.074 mill.

Jasper Therapeutics Inc
Share Performance

-24.99%

30 Days

Jasper Therapeutics Inc

Profile

Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.

More about Jasper Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 18.576 mill.	$ - mill.	$ -31.771 mill.

Contextlogic Inc
Share Performance

+91.14%

This Year

Contextlogic Inc

Profile

LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.

More about Contextlogic Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 660.900 mill.	$ 33.600 mill.	$ 117.700 mill.

Lexeo Therapeutics Inc
Share Performance

-21.00%

One Year

Lexeo Therapeutics Inc

Profile

Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.

More about Lexeo Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 363.914 mill.	$ - mill.	$ -87.265 mill.

48 more competitors available

Sources: Regenxbio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, September 14, 2026 4:04 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Regenxbio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.